Skip to content

ImGTS for Patients With Behavioral and Psychological Symptoms of Dementia

Developing an Immersive Gamification Technology System (ImGTS) for the Management of Patients With Behavioral and Psychological Symptoms of Dementia (Phase 1 Trial)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05265182
Enrollment
30
Registered
2022-03-03
Start date
2022-04-28
Completion date
2022-07-26
Last updated
2023-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dementia Alzheimers

Brief summary

The proposed research project aims to answer the question Are immersive technology systems effective in the management and treatment of patients with BPSD?. This project is composed of three phases and the current study is the first phase. The phase 1 trial aims to create an immersive technology system for managing the behavioral and psychological symptoms of dementia and determine its acceptability, usability, and safety in the healthy adult population.

Detailed description

The participants will undergo an intervention using the assigned ImGTS for four sessions (twice a week for two weeks), with a maximum of 45 minutes per session. VR trials are in 10- to 20-minute periods with introduction, orientation, and provisions for rest periods for patient comfort. During the experience, documentation of the patient's reaction and interaction with the ImGTS will be recorded by the researchers. The participants will be staying at the designated laboratory for not more than one hour. Demographic characteristics Demographic characteristics of the participant (age, sex, educational attainment, marital status, living conditions, hobbies and interests, previous experience with VE applications, existing illnesses, medications) will be collected by the researchers through a questionnaire. Personal data, such as name and contact information, will only be collected to allow the investigators to contact the participants, as needed. Safety Safety will be ensured by assessing a participant's experience of cybersickness. A cybersickness questionnaire, the Virtual Reality Sickness Questionnaire will be administered after each session. In this self-report questionnaire, nine symptoms will be rated as absent/none, slight, moderate, or severe. These symptoms are general discomfort, fatigue, eyestrain, difficulty focusing, headache, fullness of head, blurred vision, dizziness when the eyes are closed, and vertigo. Answering the questionnaire will take around 10 minutes. In the event that a participant will experience severe cybersickness, they may opt to discontinue the experience. They will be instructed to remove the HMD or to step out of the Semi-CAVE room to rest and recover from the symptoms. A medical professional will be present to monitor the participant's symptoms and to attend to them for further management. The reason(s) for discontinuing the experience will be documented. Acceptability The acceptability of the design will be measured using the Place Probe, a sense of place questionnaire. The questionnaire will be administered after each session, and it will collect information on a participant's experience in the VE application, particularly on (a) their general impression of the environment, (b) the key features of the environment, and (c) their feelings of presence. A positive general impression, a memorable environment, and high level of presence will indicate that the VE developed is acceptable. This will take about 10 minutes to complete. Usability Usability testing will be performed according to the PNS ISO/IEC Metrics. The goal is to provide continuous improvement in the design and user experience to maximize the three components of usability: effectiveness, efficiency, and satisfaction. Additional usability metrics will be identified during the first phase of the study. The metrics will be specifically adjusted to the target participants as well as the contents to be included in the VR system.

Interventions

PROCEDUREvirtual reality

Create an immersive technology system for managing the behavioral and psychological symptoms of dementia and determine its acceptability, usability, and safety in the healthy adult population initially, using semi-Cave or head-mounted display.

Sponsors

Augmented eXperience E-health Laboratory
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
OTHER
Masking
NONE

Intervention model description

HMD and Semi-Cave

Eligibility

Sex/Gender
ALL
Age
40 Years to 59 Years
Healthy volunteers
Yes

Inclusion criteria

* Aged 40 to 59 years old * Montreal Cognitive Assessment-Philippine Version (MoCA-P) score \> 20 * Neuropsychiatric Inventory (NPI) score of 0 * Able to understand Filipino and English

Exclusion criteria

* Previously diagnosed with dementia * Receptive aphasia * Previously diagnosed with a psychiatric disorder * Previously diagnosed with seizures or epilepsy * Significant visual and hearing impairment * Has a history of motion sickness * Quadriplegia or paralysis of dominant hand * Life expectancy of less than a year

Design outcomes

Primary

MeasureTime frameDescription
The incidence of cybersickness will be assessed using the Virtual Reality Sickness Questionnaire.Immediately after each intervention, within an hour of completion of the virtual reality game.A 9-item Virtual Reality Sickness Questionnaire to assess cybersickness.
The acceptability of the design will be measured using the Place Probe.Immediately after each intervention, within an hour of completion of the virtual reality game.The Place Probe is a sense of place questionnaire.
The rate of usability will be performed according to the Philippine National Standards ISO/IEC Metrics.Within an hour of the end of the study.The goal is to provide continuous improvement in the design and user experience to maximize the three components of usability: effectiveness, efficiency, and satisfaction.

Countries

Philippines

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026